Background and Aim: The purpose of this study was to assess the relationship of pleural adenosine deaminase (P-ADA) and non-Hodgkin's lymphoma (NHL). Design and Methods: We retrospectively analysed 63 NHL patients with pleural effusions who accepted a diagnostic thoracentesis and who had P-ADA available at the China Medical University Hospital (Taichung, Taiwan) between January 2003 and April 2012. Results: There were 46 exudates [40 malignant pleural effusions (MPE), 5 complicated parapneumonic effusions and 1 undiagnosed effusion] and 17 transudates. The P-ADA activity was significantly different between the two groups (P < 0.005). Among 40 MPE cases, 29 were due to B-cell and
Background
Up to 20% 1 of patients with non-Hodgkin's lymphoma (NHL) reportedly has pleural effusion. Pleural effusions in NHL are usually exudates as a result of the following mechanisms: (i) cancer with pleural involvement; (ii) chylothorax; (iii) obstructed lymphatic return by enlarged lymph nodes 2 and (iv) infections. However, when advanced NHL has generalized involvement, the pleural effusion may be a transudate. 2 The first step in the management of pleural effusion is to confirm whether it is a transudate or exudate. Light's criteria are currently the most accurate way of differentiation. 3 The weak point of Light's criteria is that they sometimes recognize effusion in a patient with congestive heart failure (CHF) on diuretics as an exudate. 3, 4 Most lymphoma patients have accepted aggressive hydration and diuresis to avoid tumor lysis syndrome in chemotherapy. These factors may influence the correct rate of differentiation of exudate from transudate, as patients with CHF receiving diuretics. 3, 4 Furthermore, the pleural effusion for the prognostic ! Crown copyright 2014.
influence of NHL is controversial. In a case-control study, pleural effusion was found not to adversely affect survival rates, 5 but the presence of malignant pleural effusion (MPE) was reported to be a poor prognostic factor. 1, 6 However, without doubt, an exact diagnosis of lymphoma effusions is important.
Adenosine deaminase (ADA) is an enzyme of purine catabolism that catalyses adenosine to inosine, and its main physiologic activity is localized in lymphoid tissue. 7 ADA activity increases when the antigenic response of lymphocytes and T-lymphocytes proliferate and the activity is 10 times higher in T-lymphocytes than in B-lymphocytes. 8, 9 Atalay et al. 10 showed that measurement of pleural ADA (P-ADA) could aid the separation of transudative and exudative pleural effusions. P-ADA is also a powerful diagnostic tool for tuberculosis (TB) pleuritis. 11, 12 When using the diagnostic cut-off value of 40 IU/l of P-ADA in lymphocyte-rich exudative effusions, the specificity rises to above 95% for TB pleuritis. [13] [14] [15] Although false-positive findings of P-ADA in the diagnosis of TB pleuritis are rare, one of the major factors is lymphoma. 12, [14] [15] [16] [17] Numerous case reports have demonstrated the increased P-ADA levels in lymphoma pleurisy, 12, [14] [15] [16] [17] but no original study has focused on the relationship of P-ADA and NHL. In a retrospective pleural effusion study, 57% (17/30) of lymphomas reached the diagnostic cut-off for TB. 12 However, the etiologies of lymphoma effusions include MPE, chylothorax and complicated parapneumonic effusion (CPPE). CPPE also had higher P-ADA levels. 14, 15, 18 So, the association of MPE and P-ADA in lymphoma patients is still unclear. Moreover, there has been no study discussing P-ADA activity in T-cell or B-cell NHL.
We therefore hypothesized that determination of P-ADA may aid the separation of transudates from exudates and have great value in distinguishing MPE from other effusions in lymphoma patients. P-ADA may have a higher level of activity in T-cell than B-cell NHL. The purpose of this study was to assess the correlation of P-ADA in NHL. To our knowledge, this may be the first large-scale study of lymphoma patients to focus on this issue.
Materials and Methods

Identified patients
After approval from the institutional review board (DMR101-IRB2-247), we retrospectively analysed all NHL patients with pleural effusions who had accepted a diagnostic thoracentesis and whose P-ADA was available at the China Medical University Hospital (Taichung, Taiwan), a 2000-plus bed medical centre and teaching hospital, between January 2003 and April 2012. Of the NHL patients with pleural effusions requiring repeat tapping, only the first thoracentesis was used. Sixty-three pleural fluid samples were selected.
The routine tests for pleural fluid in the study hospital included biochemical studies of pleural/serum lactate dehydrogenase (LDH) and protein, complete cell counts with differential count, bacterial culture, acid-fast bacilli smear and culture, triglycerides and cytology. If the drainage effusions were more than 60 cc, cell blocks and immunohistochemistry were performed. 19 Detailed radiographic and clinical findings, demographic data and laboratory results were carefully reviewed from medical records.
P-ADA activity (units/l) was determined by enzyme assay using the automated ultraviolet-rate method (Nisseiken Co., Ltd., Japan), consisted of two steps: first, adenosine was deaminated by ADA and ammonia was released; then, the ammonia created by the catalytic activity of ADA was linked to the reaction catalysed by glutamate dehydrogenase. The decrease in absorbance at 340 nm (conversion of NADPH to NADP+) has a direct relationship to the ADA activity. A P-ADA level reaching the diagnostic cut-off for TB (40 IU/ l) 13, 20, 21 was defined as an abnormality. Effusions were classified into transudates and exudates following Light's criteria, and afterwards, the results obtained were (or not) corroborated with patients' clinical presentation. Transudates were defined based on imbalances in oncotic and hydrostatic pressure, such as CHF, liver cirrhosis and hypoalbumenia. Exudates develop when local factors, such as malignant effusions, chylothorax and CPPE, affect the accumulation of pleural effusions.
The pleural effusions were diagnosed as follows: CHF was considered when echocardiography showed lower ventricular function or radiography revealed pulmonary venous congestion and response to CHF treatment; liver cirrhosis was determined as the cause of the pleural effusions by clinical evidence of portal hypertension, hepatic injury and/or ascites; hypoalbuminemia was defined by a serum albumin level <30 g/l in the absence of proteinuria and liver cirrhosis; neoplastic effusions were recognized when one of the following criteria was met: (i) there was significant nodular pleural thickening in computer tomography scans 22 and response to chemotherapy (ii) there was histologic or cytologic evidence of MPEs. CPPE referred to those non-purulent-appearing effusions with pH < 7.20, glucose < 40 mg/dl, Gram's stain or culture positive that required tube drainage or surgery.
A triglyceride concentration of > 110 mg/dl in the pleural fluid was considered to be chylothorax. Undiagnosed effusions were defined as those in a lymphoma patient whose repeat pleural cytology and chest image could not demonstrate malignancy and for whom there was no obvious definite diagnosis. Undiagnosed effusions are usually associated with enlarged mediastinal or hilar lymph nodes interfering with lymphatic return. 2 The final diagnoses of the pleural effusions were independently verified by at least one senior pulmonologist.
Statistical analysis
Categorical and continuous data are presented as numbers (percentages) and medians (25th, 75th percentile), respectively. Chi-square and Fisher's exact test were used to assess differences in categorical variables between groups. The nonparametric Mann-Whitney U-test was used for continuous variables. Among subgroups, comparisons of quantitative variables were performed with the nonparametric Kruskal-Wallis one-way test. The data of P-ADA for differentiation of transudates and exudates were analysed by diagnostic efficiency derived from the receiver operating characteristic (ROC) curve. Two-tailed P values 40.05 were considered statistically significant. All statistical analyses were conducted with SPSS software, version 17.0 (SPSS Inc., Chicago, IL).
Results
The characteristics of the 63 NHL patients with pleural effusions who underwent diagnostic thoracentesis with P-ADA examination were analysed. The major etiology of the effusions in lymphoma patients was malignancy (n = 40; 63%), followed by systemic factor-induced transudates (n = 17; 27%), CPPE (n = 5; 8%) and undiagnosed exudative effusions caused by enlarged hilar or mediastinal lymph nodes with obstructed lymphatic return (n = 1; 2%) ( Table 1) .
There were 44 (70%) patients with B-cell lymphoma [i.e. diffuse large B-cell lymphoma (n = 22; 35%), follicular lymphoma (n = 4; 6%), chronic lymphocytic leukaemia (n = 3; 5%) and other Bcell lymphoma (n = 15; 24%)] and 19 (30%) with T-cell lymphoma [i.e. peripheral T-cell lymphoma not otherwise specified (n = 7; 11%), angio-immunoblastic T-cell lymphoma (n = 4; 6%) and other T-cell lymphoma (n = 8; 13%)]. There were 42 men and 21 women, with a mean age of 62 years. Twenty-six patients (41%) had bilateral pleural effusions, 15 (24%) had right pleural effusions and 22 (35%) had left pleural effusions (Table 2) .
Diagnostic accuracy of tests that differentiated exudates from transudates in 63 NHL patients is presented in Table 3 . Using the Light's criteria in 63 NHL with effusions, 9 (14%) effusions were incorrectly classified. Seven transudates were misclassified as exudates and two exudates were misclassified as transudates. The sensitivity, specificity, positive likelihood ratio and negative likelihood ratio for exudate in Light's criteria were 96%, 59%, 2.32 and 0.07, respectively. P-ADA activity differed significantly between transudates and exudates in NHL patients (P = 0.005) ( Table 2 and Figure 1 ), and the optimum cut-off levels for P-ADA was 26 IU/l. Although P-ADA level 5 26 IU/l had a specificity of 100% (95% confidence interval, 77-100) for identifying an exudative effusion, the sensitivity was 52% and the area under the ROC curve was only 0.731.
There was no variable with a significant difference between the MPE of B-cell and T-cell NHL (Table 4) . The median levels (25th, 75th percentile) of P-ADA were 28 IU/l (14-50) in the MPE of B-cell NHL and 26 IU/l (14-28) in the T-cell NHL (P = 0.693).
In the various subclasses of exudative effusions in lymphoma patients, the P-ADA level reached the diagnostic cut-off for TB (40 IU/l) in 11 cases of MPE (11/40 = 27.5%): 9 B-cell NHLs (9/29 = 31%) and 2 T-cell NHLs (2/11 = 18%). There were no differences in the P-ADA level among the three groups' exudates (MPE of B-cell and T-cell NHL and CPPE) (Figure 2 ).
There were weak correlations between the P-ADA levels and the various hematologic and biochemical parameters, especially the protein and LDH concentrations in the pleural fluids (Table 5) .
Discussion
Although the presence of elevated P-ADA levels in NHL is well established, 12,14-17 our study is the first that has systematically documented the frequency of this event in the different categories of lymphoma. In this largest series focusing on MPE of NHL, we found that only 27.5% of patients had P-ADA levels over 40 IU/l. The P-ADA activity in T-cell lymphoma was not higher than that in B-cell lymphoma. , diffuse large B-cell lymphoma; FL, follicular lymphoma; CLL, chronic lymphocytic leukaemia; PTCL-NOS, peripheral T-cell lymphoma not otherwise specified; AITL, angioimmunoblastic T-cell lymphoma; P-ADA, pleural adenosine deiminase. *P < 0.05. Light's criteria identify correctly 98% of pleural exudates and misclassify 17% of transudates as exudates. 3 The following characteristics of NHL patients resulted in difficulty distinguishing transudates from exudates using Light's criteria: (i) frequently aggressive hydration and diuresis to avoid tumor lysis syndrome in chemotherapy and (ii) higher serum LDH influencing the pleural LDH level. In our series, differentiation of transudates and exudates in NHL effusions using Light's criteria had a 14% misclassification rate. The specificity for exudates was only 59% and misclassified 41% (N = 7/ 17) of transudates as exudates.
Atalay et al. 10 found that P-ADA could aid the separation of pleural exudates from transudates and the accuracy was similar to that of the albumin gradient. In our series focusing on NHL effusions, P-ADA activity was also significantly different between transudates and exudates (P = 0.005). The optimum cut-off levels for P-ADA was 26 IU/l, relative higher than the published work of Atalay et al.
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Because of 100% specificity, there was no P-ADA 5 26 IU/l in transudative NHL effusion. However, the area under the ROC curve was only 0.731.
The ADA level is determined by activation of cellular immunity, where it plays a role in the differentiation of lymphoid cells and the maturation of monocytes to macrophages.
7-9 P-ADA activity is related to the pleural maturity of T-lymphocytes and is classically associated with TB, CPPE and lymphoma. 11, 12, [14] [15] [16] [17] The measured techniques of ADA levels have been broadly categorized into two groups: Giusti method versus non-Giusti methods. 23 The cut-off values of ADA in various fluids by non-Giusti automated method with commercial kit were relative lower than Giusti method. 12, 21, 23 However, the most widely accepted cut-off value for P-ADA is 40 IU/l in TB pleuritis, 13, 20, 21 and we also defined P-ADA over 40 IU/l as an abnormality in our series. When the P-ADA levels were higher than 250 IU/l, the possible diagnosis was CPPE or lymphoid malignancies instead of TB pleurisy. 13 A precursor T lymphoblastic lymphoma patient in our study had a P-ADA test exceeding 250 IU/l.
However, the average P-ADA activity in lymphoma was lower than we had guessed. Why P-ADA activities are not associated with T-cell NHL and Figure 2 . P-ADA levels in different diagnostic groups of NHL. Bar indicates the median value of the group. The P-ADA levels of the three groups' exudates (MPE of B-cell and T-cell lymphoma and CPPE) showed no difference. Undiagnosed pleural effusion was not included in the statistics due to the small sample size. only 27.5% of MPE in NHL has higher P-ADA levels are interesting questions and may be explained by the following: (i) P-ADA activity is nearly unaffected by the white cell count (R = 0.271), whether neutrophils (R = 0.187) or monocytes (R = 0.3), compatible with previous reports 11, 12, 14 and (ii) the NHL patients are in an immuno-compromised status 24 and the immature T-lymphocyte reproduction cannot reflect the amount of enzyme present. However, other pleural fluid biochemistries, such as protein and LDH had relatively good correlations (R = 0.495 and 0.407, respectively) with P-ADA activity. This may be due to the concentrations of pleural protein and LDH reflecting the metabolic rate of local cancer and interaction with P-ADA levels.
This study has several limitations. First, serumpleural fluid albumin gradient, pleural to serum albumin ratio and NT-proBNP value were not obtained to try and improve accuracy of differentiation of transudates and exudates in NHL patients. 4 Second, ADA represents the sum of two isoforms of ADA1 and ADA2. 13, 20 In this retrospective NHL effusions study, we do not know what the major source of ADA activity is. Third, the total number of exudative effusions due to MPE in this study, mostly T-cell lymphoma, is low, so conclusions in regard to the distribution of P-ADA value in this type of lymphoma should be taken with caution. Fourth, being a single-centre retrospective study, the generalizability of the results to other hospitals is unknown. However, the validity of the study is not decreased, because the etiologies of the NHL effusions were identified with standard diagnostic criteria.
In conclusion, the use of P-ADA in NHL effusion could aid the separation of transudates from exudates. The P-ADA levels could be mildly predicted from LDH and protein. Around one-quarter of MPE in NHL had abnormal P-ADA (>40 IU/l). The P-ADA activity in T-cell and B-cell NHL showed no difference.
